Consider a group like this one. Dana Whitfield runs eleven locations across the Kansas City metro, up from four in 2019, and has had the same conversation with the same banker three times in eighteen months. Production is up. New patients are flat, which Dana has been calling stable. Then a buyer's analyst sends over a list of the eleven locations with a note that they could only find seven of them, and the two acquired most recently were still showing the previous owners' details. Dana had been waiting for a better multiple. What Dana was actually doing was waiting while the thing a buyer pays for quietly thinned out. This is a pattern that appears across the data, and it rarely announces itself in the numbers you already watch.
The question of whether to sell your dental practice to a DSO now or wait for a higher multiple has probably crossed your desk more than once, usually late, usually alone. One number you could accept today against a number you believe two more years of work would earn. Neither feels solid. Both depend on things you do not control: rate environments, buyer appetite, how quickly groups your size get absorbed in your metros. What you do control is narrower than the model suggests, and more decisive. Across 201,000+ US practices, the clearest separator between groups that sell well and groups that sell adequately is not size, and it is not age. It is whether new patients still arrive under their own power.
Why does this decision feel harder than it did two years ago?
Because the inputs moved underneath you. Dentistry is a $179.4 billion market and roughly 32% of it now sits inside group ownership. That share did not arrive all at once. It arrived one tuck-in at a time, in metros that looked wide open right up until they were consolidated. Your group sits somewhere on that curve. If your markets are early on it, holding can genuinely pay. If your markets are late, holding means competing for the same buyers with less scarcity working in your favour.
The harder change is on the demand side. There are 432,000 AI-assisted dental searches every month, and most practices do not appear in them at all. Your locations either surface in that channel or they do not, and the answer tends to be consistent across every site you own. That consistency is exactly what turns it into a valuation input rather than an operational annoyance. A buyer underwriting your next five years is underwriting patient flow. You are deciding whether to sell that flow at today's price or bet that you can widen it first.
What is a buyer actually paying for when they pay a premium multiple?
Not your chairs. Not last year's collections. They are paying for the probability that patient volume continues without them having to purchase it. Every diligence conversation reduces to that question eventually, even when it arrives dressed in other language.
This is where the discovery channel matters more than most sellers expect. 82% of dental searches end in a Maps interaction, which means the majority of your future patients choose between you and someone else inside a listing panel, before they read your site or hear your name from anyone. Practices with complete, well-structured profiles see 7x more clicks than those without. Your group either owns that moment across every location or it leaks it quietly, daily, in a way no line on your P&L will ever name.
A buyer with any sophistication checks. The Dental Index national practice audit found that 70% of practices are invisible to AI-assisted search, and your locations are inside that distribution somewhere. If your name does not surface, the growth assumptions in your model become their risk. Risk gets priced. Premium multiples follow durable demand, and durable demand follows visibility you are not renting.
Is your patient acquisition trending up, flat, or quietly down?
Most operators cannot answer this cleanly, because the total new-patient number hides the mix. A group can post flat new patients for four consecutive quarters while the source shifts underneath from unpaid discovery to referral to paid, with cost per acquisition climbing the whole way. On paper, stability. Underneath, erosion that only becomes visible when someone freezes the spend.
The average practice scores below 40 out of 100 on AI readiness, and only 8% clear 65. That distribution matters to you specifically, because it means the ceiling in most of your markets is low and genuinely reachable. You are not fighting a field of well-positioned competitors. You are fighting inertia, theirs and your own.
Pull your trailing eighteen months by channel rather than by total. If unpaid discovery is a shrinking share of new patients, your trajectory is already bending, and it will keep bending through the diligence window whether you sell or hold. If it is holding or growing, you own something a buyer will pay for and something you can compound. Those are opposite situations calling for opposite decisions, and the headline number tells you nothing about which one you are in.
What does a buyer see when they look up your locations the way a patient would?
Run it yourself before they do. Pick three locations: your strongest, your median, and the one you inherited in an acquisition and never fully integrated. Search the way a patient in that ZIP would, including the AI-assisted route. Note what comes back and in what order.
- The flagship usually performs. It has the review volume, the history, the complete profile, and a front desk that maintains it without being asked.
- The median location is where drift shows first. Present, findable, but ranked behind practices producing a fraction of what it produces.
- The recent tuck-in is often absent entirely, still carrying the previous owner's details, or represented so thinly that no engine has enough to name it.
The pattern that shows up across the audit is that groups are inconsistent by location rather than uniformly weak. Since roughly seven in ten practices do not appear in AI-assisted results, the odds that every site you own is represented are slim. That inconsistency is legible in diligence. A buyer looking at eleven locations and finding four of them unfindable does not read it as a dental acquisition strategy gap. They read it as integration risk, which is the specific risk that most reliably compresses multiples for groups your size.
Are you waiting for the market, or waiting for yourself?
This is the honest version of the timing question and it is worth sitting with for a minute. Waiting for the market means you believe buyer appetite or the rate environment will improve and lift your number without you changing anything about the business. That is a bet on conditions. You have no influence over it and no way to time it, and you will only know whether you were right after the window closes.
Waiting for yourself is something different. It means you have identified a specific gap between what your group produces and what it could produce, you know what closes it, and you want the corrected numbers sitting in your trailing twelve before you go to market. That is a bet on execution, and it is the only version of waiting with an actual mechanism behind it.
If your reason for holding is the first kind, more time mostly adds exposure. If it is the second, the question becomes narrow and answerable: what improves, by when, and does it show up in the metrics a buyer weights? Most operators, pressed on this, find they have been telling themselves the first story while believing it was the second.
How much of your enterprise value is sitting in procedures you are not being found for?
Look at composition, not just totals. Implants are growing 8.5% a year at roughly $4,500 per case. Cosmetic runs 6.8% at $3,800. Orthodontics sits at 5.1% and $5,500. These are the lines that move enterprise value, because they carry margin and they signal that a group can grow revenue without adding operatories or providers.
Now ask which of your locations actually surface for those procedures in their own markets. In most groups the answer is one or two, and the remainder are found for general dentistry or not found at all. Patients who arrive through AI-assisted discovery book high-value treatment at two to three times the rate of other channels. Your case mix, in other words, is partly a downstream effect of how you are discovered, not only of how well your clinicians present treatment.
The average solo practice leaves about $147,000 unrealised each year. Run that underlying pattern across a group of your size and the gap stops being a rounding error. It is the difference between a growth story you can evidence with a trend line and one you have to argue for in a management presentation.
What does the pace of consolidation tell you about the window you are in?
Group ownership holds roughly 32% of a $179.4 billion market spread across more than 201,000 practices. The arithmetic cuts both ways for you. There is a long runway of independent practices still to absorb, which supports continued buyer activity for years. There is also a steadily shrinking pool of unconsolidated metros, which means the scarcity value your particular footprint carries is not permanent and is not renewable.
Cost pressure layers on top. 33.9% of practices are actively recruiting hygienists, and that competition does not stay contained in the staffing line. It shows up in chair utilisation, in unfilled schedule blocks, in the productivity assumptions a buyer models forward. A group that has to buy patient volume and buy clinical capacity at the same time is defending two margins simultaneously, and buyers can see both.
None of this argues that you should rush. It argues that the case for waiting has to rest on something specific improving, because the ambient conditions are not clearly moving in your favour. Waiting inside a consolidating market without a plan is not patience.
Waiting inside a consolidating market without a plan is not patience. It is drift with a deadline you do not control.
What happens to your multiple if growth depends on paid patient acquisition?
A buyer will separate your new patients into two groups: the ones who arrived because they found you, and the ones who arrived because you paid for the introduction. Both count toward volume. They are not valued the same, because one continues after close at no incremental cost and the other is a recurring obligation the buyer inherits on day one.
This is where a discovery gap stops being operational and becomes a valuation gap. If seven in ten practices are absent from AI-assisted search and yours is among them, the volume still has to come from somewhere, and it comes from spend. Your cost per new patient becomes structural rather than discretionary, which is exactly how a diligence team will characterise it in their memo.
The reverse is more useful to you. Every point of unpaid discovery you build before a sale converts a variable cost into an asset that transfers with the entity. You are not making the group look better. You are changing what the group is. A practice whose patient flow survives a spend freeze gets underwritten differently than one whose flow does not, and both sides of the table understand that.
How do you tell a soft quarter from a change in trajectory?
A soft quarter has a cause you can name: a provider on leave, a location mid-renovation, a seasonal dip that lands in the same month every year and always has. A trajectory change has no such story. It reads as ordinary noise for three quarters, and then it is simply the new baseline and nobody can point to when it started.
The reliable test is directional rather than statistical. Is the share of new patients who found you without paid help rising, flat, or falling across eighteen months? Is that pattern uniform across locations or isolated to one? Isolated points to an operational cause with an operational fix. Uniform points to a positioning cause, and positioning causes do not self-correct with time or effort.
Most groups misdiagnose this in the same direction. They treat a uniform decline as a series of local problems and answer with local responses: a promotion in one market, a schedule change in another, more spend where it hurts most. The data runs the other way. When most locations drift at once, the shared input is how the group is found.
Timing is an output, not an input
Operators who get this decision right stop treating the calendar as the variable. They understand that the right moment is defined by their own trend line, not by a rate cycle or a rumour about buyer appetite. Once the trajectory is clear, the timing answers itself.
Patient flow is the asset, not the practice
The groups that command the numbers they want think of themselves as owning demand rather than owning locations. Chairs and staff can be rebuilt anywhere. A reliable stream of patients who find you without being paid for is the part that is genuinely hard to replicate, and they price themselves accordingly.
Diligence is a mirror, not a test
Sellers who avoid surprises stop thinking of diligence as something done to them. They run the same checks a buyer runs, months earlier, and treat what comes back as information about their own business rather than as a grade. Nothing in a buyer's memo should be news to you.
Uniform problems have single causes
When every location softens at once, experienced operators resist the instinct to solve it eleven times. They look for the one shared input all of those locations depend on. Almost always it is how the group is found, which is why local fixes keep producing local, temporary improvements.
What does a diligence team check that your dashboard does not?
Your dashboard reports outcomes: production, collections, new patients, case acceptance, hygiene reappointment. A diligence team reads all of that too, and then goes looking for what produced it. That second layer is where sellers get caught flat.
- Location-level findability, tested by searching each site the way a local patient would, including the AI-assisted route.
- Profile completeness and consistency across every location, since that is what determines whether the engines can name you at all.
- Procedure-level presence, specifically whether your highest-value lines surface in the markets that are supposed to carry them.
None of that appears on your dashboard, and all of it shapes the assumptions behind their model. The asymmetry is worth naming plainly: you are optimising what you measure, and they are measuring what you have not been looking at. With only 8% of practices clearing an AI readiness score of 65, most sellers walk in without knowing where they stand and learn their position from a buyer's memo. The information exists either way. The only variable is who sees it first, and how much time that leaves you.
| Valuation signal | Group positioned for discovery | Group without positioning |
|---|---|---|
| Presence in AI-assisted search | Inside the 8% scoring above 65 on AI readiness | Inside the 70% absent from AI results entirely |
| Profile completeness | Up to 7x more clicks from the same search volume | Baseline visibility, ranked behind smaller competitors |
| Maps interaction capture | Captures its share of the 82% of searches ending in Maps | Same 82% of searches route to the practice nearby |
| High-value case mix | AI-referred patients book high-value treatment at 2-3x the rate | Mix weighted toward general dentistry and emergencies |
| Cost of new patient volume | Largely unpaid, transfers intact at close | Structural spend the acquirer inherits |
The Dental Index national practice audit · 2026
If you decide to wait, what has to be true in eighteen months?
Make the condition explicit, in writing, because a vague intention to wait quietly becomes a default. Name what improves and how you would recognise it: unpaid discovery as a share of new patients, the consistency of that share across every location you own, whether your highest-value procedure lines are visible in the markets that are meant to carry them.
Then decide in advance what you do if those numbers have not moved. That is the step most operators skip, and it is the one that determines whether waiting was a decision or an avoidance wearing a decision's clothes. If eighteen months pass and the trajectory is unchanged, you will be selling the same group into an older market with less runway behind it and one more year of consolidation ahead of it.
The version of waiting that works is narrow. You are holding because you have found a fixable gap, you are fixing it, and you want the corrected trend line in your trailing twelve. Everything else is hoping, and a buyer reading your national audit position will not distinguish between the two.
Whatever you decide, decide it with your actual position in front of you rather than the one you assume you have. Your locations are either surfacing in the searches your future patients are already running or they are not, and that answer sits underneath your multiple whether you look at it or not. A group that can demonstrate durable, unpaid patient flow across every site it owns is telling a story a buyer can underwrite line by line. A group that cannot is asking the buyer to carry that risk instead, and buyers price risk for a living. Clear positioning is what makes AI search and Maps ranking work at all. Invisible positioning means an invisible practice, no matter how well you run it or how much you spend. That holds on the day you sign, and every day you wait.